Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SALVATORE Q NAPOLI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1588715882
CMS profile
207693
Location
FOXBORO, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$131,811.05

243 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 5 of 5; records 201–243 of 243 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SALVATORE Q NAPOLI

NPI 1588715882 · CMS profile ID 207693

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

FOXBORO, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–243 of 243 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588715882?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SALVATORE Q NAPOLI, NPI 1588715882, CMS profile ID 207693. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–243 of 243 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588715882?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SALVATORE Q NAPOLI, NPI 1588715882, CMS profile ID 207693. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–243 of 243 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588715882?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SALVATORE Q NAPOLI, NPI 1588715882, CMS profile ID 207693, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–243 of 243 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1588715882?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

243 matching records · $131,811.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 243 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–243 of 243.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $22.6602/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681248333 CMS
Mallinckrodt Enterprises LLC $18.2802/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704790599 CMS
Acorda Therapeutics, Inc $15.8102/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633501457 CMS
Biogen, Inc. $3,150.0002/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660659077 CMS
GENZYME CORPORATION $18.6602/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693926047 CMS
Novartis Pharmaceuticals Corporation $11.6702/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659917601 CMS
Sunovion Pharmaceuticals Inc. $17.7202/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688050379 CMS
Celgene Corporation $40.0002/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672718757 CMS
Celgene Corporation $30.0002/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672720273 CMS
Celgene Corporation $55.0002/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672720339 CMS
Celgene Corporation $30.0002/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672720581 CMS
GENZYME CORPORATION $247.8102/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694239211 CMS
GENZYME CORPORATION $117.6702/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694239213 CMS
GENZYME CORPORATION $46.1302/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694239215 CMS
GENZYME CORPORATION $52.4402/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694239217 CMS
GENZYME CORPORATION $64.5902/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694239219 CMS
GENZYME CORPORATION $3,797.5002/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694239221 CMS
GENZYME CORPORATION $371.5902/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694316039 CMS
Mallinckrodt Enterprises LLC $7.2802/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704790597 CMS
Celgene Corporation $715.7102/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672719517 CMS
Celgene Corporation $189.4402/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672720401 CMS
Celgene Corporation $690.7102/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672735955 CMS
Mitsubishi Tanabe Pharma America, Inc. $13.1002/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703744053 CMS
Novartis Pharmaceuticals Corporation $16.3902/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659917577 CMS
Vertical Pharmaceuticals, LLC $20.3702/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675509317 CMS
Allergan Inc. $16.4801/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670864357 CMS
Neurocrine Biosciences, Inc. $18.1201/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693150679 CMS
GENZYME CORPORATION $14.5901/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693933403 CMS
GENZYME CORPORATION $1,715.0001/26/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694286869 CMS
Novartis Pharmaceuticals Corporation $2,660.0001/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659917567 CMS
Novartis Pharmaceuticals Corporation $114.8101/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659917569 CMS
Alexion Pharmaceuticals, Inc. $20.7801/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695568889 CMS
Biogen, Inc. $4,050.0001/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660659075 CMS
Biogen, Inc. $364.0201/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660659085 CMS
Mallinckrodt Enterprises LLC $28.9901/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704790595 CMS
Amneal Pharmaceuticals LLC $12.2401/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692320753 CMS
Lilly USA, LLC $17.5001/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658122383 CMS
Biogen, Inc. $10.8501/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660659097 CMS
Supernus Pharmaceuticals, Inc. $17.0801/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702337457 CMS
PFIZER INC. $10.8601/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672249349 CMS
Novartis Pharmaceuticals Corporation $5.2601/10/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659917603 CMS
Novartis Pharmaceuticals Corporation $6.6601/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659917591 CMS
Mallinckrodt Enterprises LLC $1,980.0001/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704790593 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $131,811.05 243
PY2020 $77,858.77 123
PY2021 $67,779.22 134
PY2022 $81,496.85 157
PY2023 $110,442.82 240
PY2024 $87,634.14 200
PY2025 $55,859.47 145

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $538,522.21 159
PY2024 Principal investigator $417,660.23 91
PY2023 Principal investigator $531,336.33 84
PY2022 Principal investigator $551,859.15 23
PY2021 Principal investigator $370,200.56 56
PY2020 Principal investigator $131,144.09 36
PY2019 Principal investigator $96,940.86 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

159 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $28.24 12/29/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200097
Principal investigator 1 Ipsen Innovation $1,050.00 12/23/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289298
Principal investigator 1 Ipsen Innovation $1,050.00 12/23/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289300
Principal investigator 1 Ipsen Innovation $1,050.00 12/23/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289304
Principal investigator 1 TG Therapeutics, Inc. $6,521.03 12/09/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200093
Principal investigator 1 Ipsen Innovation $44.19 12/01/2025 Non-covered Recipient Entity
Neurology Center Of New England
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289294
Principal investigator 1 Ipsen Innovation $4,928.22 12/01/2025 Non-covered Recipient Entity
Neurology Center Of New England
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289296
Principal investigator 1 Ipsen Innovation $4.96 12/01/2025 Non-covered Recipient Entity
Neurology Center Of New England
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289302
Principal investigator 1 Ipsen Innovation $3.44 12/01/2025 Non-covered Recipient Entity
Neurology Center Of New England
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289306
Principal investigator 1 Ipsen Innovation $3,850.00 11/28/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289276
Principal investigator 1 Ipsen Innovation $1,050.00 11/28/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289280
Principal investigator 1 Ipsen Innovation $1,050.00 11/28/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289282
Principal investigator 1 Ipsen Innovation $3,850.00 11/28/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289284
Principal investigator 1 Ipsen Innovation $4,970.00 11/28/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289286
Principal investigator 1 Ipsen Innovation $450.00 11/21/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289256
Principal investigator 1 Ipsen Innovation $270.00 11/21/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289258
Principal investigator 1 Ipsen Innovation $90.00 11/21/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289260
Principal investigator 1 Ipsen Innovation $270.00 11/21/2025 Non-covered Recipient Entity
Neurology Center Of New England
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289268
Principal investigator 1 Ipsen Innovation $150.00 11/21/2025 Non-covered Recipient Entity
Neurology Center Of New England
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289270
Principal investigator 1 Ipsen Innovation $450.00 11/21/2025 Non-covered Recipient Entity
Neurology Center Of New England
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289272
Principal investigator 1 Merz Pharmaceuticals, LLC $6,500.00 11/17/2025 Non-covered Recipient Entity
Neurology Center of New England, PC
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647438
Principal investigator 1 Ipsen Innovation $150.00 11/06/2025 Non-covered Recipient Entity
Neurology Center Of New England
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289274
Principal investigator 1 Ipsen Innovation $180.00 11/05/2025 Non-covered Recipient Entity
Neurology Center Of New England
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289262
Principal investigator 1 Ipsen Innovation $300.00 11/05/2025 Non-covered Recipient Entity
Neurology Center Of New England
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289264
Principal investigator 1 Ipsen Innovation $300.00 11/05/2025 Non-covered Recipient Entity
Neurology Center Of New England
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289266
Principal investigator 1 Ipsen Innovation $4,900.00 11/05/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289278
Principal investigator 1 Ipsen Innovation $14.02 11/05/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289288
Principal investigator 1 Ipsen Innovation $12.76 11/05/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289290
Principal investigator 1 Ipsen Innovation $10.08 11/05/2025 Non-covered Recipient Entity
Neurology Center Of New England
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289292
Principal investigator 1 TG Therapeutics, Inc. $3,787.00 11/01/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200091
Principal investigator 1 Ipsen Innovation $6.38 10/31/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288648
Principal investigator 1 Ipsen Innovation $5.04 10/31/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288650
Principal investigator 1 Ipsen Innovation $10,000.00 10/31/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288656
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288644
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288646
Principal investigator 1 Ipsen Innovation $1,855.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288652
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288654
Principal investigator 1 Ipsen Innovation $3,850.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288660
Principal investigator 1 Ipsen Innovation $175.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288662
Principal investigator 1 Ipsen Innovation $1,855.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288668
Principal investigator 1 Ipsen Innovation $1,855.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288670
Principal investigator 1 Ipsen Innovation $3,850.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288672
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288674
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288676
Principal investigator 1 Ipsen Innovation $175.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288678
Principal investigator 1 Ipsen Innovation $90.00 10/16/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288664
Principal investigator 1 Ipsen Innovation $450.00 10/16/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288666
Principal investigator 1 Ipsen Innovation $819.84 10/10/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288658
Principal investigator 1 SK Life Science, Inc. $3,000.00 10/10/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
YKP3089C049 No dispute reported 06/30/2026 1252275213
Principal investigator 1 SK Life Science, Inc. $3,000.00 10/10/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
YKP3089C049 No dispute reported 06/30/2026 1252275215
Principal investigator 1 Novartis Pharmaceuticals Corporation $818.51 10/01/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND, PC
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190308750
Principal investigator 1 TG Therapeutics, Inc. $883.78 10/01/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200095
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627799
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627802
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627806
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627809
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627812
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627818
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627822
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627827
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627831
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627834
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627838
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627842
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627846
Principal investigator 1 Roche Products Limited $67.60 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627851
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627855
Principal investigator 1 Ipsen Innovation $200.00 09/17/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288640
Principal investigator 1 Ipsen Innovation $500.00 09/17/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288642
Principal investigator 1 H. Lundbeck A S $11,500.00 09/08/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774381
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,465.31 09/01/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND, PC
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190308752
Principal investigator 1 TG Therapeutics, Inc. $3,787.00 08/31/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200061
Principal investigator 1 Ipsen Innovation $4,900.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288612
Principal investigator 1 Ipsen Innovation $4,970.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288614
Principal investigator 1 Ipsen Innovation $4,900.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288616
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288620
Principal investigator 1 Ipsen Innovation $4,900.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288622
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288624
Principal investigator 1 Ipsen Innovation $1,855.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288626
Principal investigator 1 Ipsen Innovation $275.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288628
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288630
Principal investigator 1 Ipsen Innovation $4,970.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288634
Principal investigator 1 Ipsen Innovation $4,900.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288636
Principal investigator 1 Ipsen Innovation $4,970.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288638
Principal investigator 1 GENZYME CORPORATION $25,165.00 08/11/2025 Non-covered Recipient Entity
Neurology Center Of New England Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226082766
Principal investigator 1 Ipsen Innovation $10,000.00 08/07/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288618
Principal investigator 1 Ipsen Innovation $2,000.00 08/07/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288632
Principal investigator 1 Ipsen Innovation $300.00 07/31/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288594
Principal investigator 1 TG Therapeutics, Inc. $11,984.91 07/31/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200063
Principal investigator 1 Ipsen Innovation $175.00 07/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288602
Principal investigator 1 Ipsen Innovation $175.00 07/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288604
Principal investigator 1 Ipsen Innovation $4,970.00 07/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288606
Principal investigator 1 Ipsen Innovation $4,900.00 07/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288608
Principal investigator 1 Ipsen Innovation $1,050.00 07/28/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288610
Principal investigator 1 Ipsen Innovation $90.00 07/22/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288598
Principal investigator 1 Ipsen Innovation $450.00 07/22/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288600
Principal investigator 1 Ipsen Innovation $300.00 07/03/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288596
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288578
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288580
Principal investigator 1 Ipsen Innovation $4,970.00 06/30/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288582
Principal investigator 1 Ipsen Innovation $1,855.00 06/30/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288584
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288586
Principal investigator 1 Ipsen Innovation $4,900.00 06/30/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288588
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288590
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288592
Principal investigator 1 Genentech, Inc. $11,500.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211627859
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627736
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627740
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627745
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627748
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627752
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627757
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627760
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627765
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627768
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627773
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627777
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627782
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627786
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627790
Principal investigator 1 Roche Products Limited $338.00 06/25/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627795
Principal investigator 1 EMD Serono, Inc. $2,500.00 06/16/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118441
Principal investigator 1 EMD Serono, Inc. $2,500.00 06/16/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118443
Principal investigator 1 Ipsen Innovation $90.00 06/11/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288572
Principal investigator 1 Ipsen Innovation $150.00 06/11/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288574
Principal investigator 1 Ipsen Innovation $150.00 06/11/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288576
Principal investigator 1 TG Therapeutics, Inc. $7,562.00 06/01/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200031
Principal investigator 1 Ipsen Innovation $450.00 05/23/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288554
Principal investigator 1 Ipsen Innovation $270.00 05/23/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288556
Principal investigator 1 Ipsen Innovation $450.00 05/23/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288558
Principal investigator 1 Ipsen Innovation $180.00 05/20/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288566
Principal investigator 1 Ipsen Innovation $300.00 05/20/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288568
Principal investigator 1 Ipsen Innovation $300.00 05/20/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288570
Principal investigator 1 Ipsen Innovation $150.00 05/09/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288560
Principal investigator 1 Ipsen Innovation $90.00 05/09/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288562
Principal investigator 1 Ipsen Innovation $150.00 05/09/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288564
Principal investigator 1 Ipsen Innovation $10,000.00 04/30/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288546
Principal investigator 1 Ipsen Innovation $2,000.00 04/30/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288552
Principal investigator 1 Ipsen Innovation $180.00 04/21/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288544
Principal investigator 1 Ipsen Innovation $300.00 04/21/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288548
Principal investigator 1 Ipsen Innovation $300.00 04/21/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288550
Principal investigator 1 Celgene Corporation $6,250.00 04/09/2025 Non-covered Recipient Entity
Neurology Center Of New England, PC
A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOLOGICAL RESPONSE TO, AND THE SAFETY OF, THREE PARENTERALLY ADMINISTERED VACCINES IN SUBJECTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO RECEIVE ORAL OZANIMOD, NON-PEGYLATED INTERFERON-, OR NO DISEASE MODIFYING THERAPY No dispute reported 06/30/2026 1222306251
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $820.00 04/04/2025 Non-covered Recipient Entity
Advarra
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235999245
Principal investigator 1 TG Therapeutics, Inc. $39,774.00 03/31/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200025
Principal investigator 1 TG Therapeutics, Inc. $866.49 03/31/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200029
Principal investigator 1 GENZYME CORPORATION $17,500.00 03/24/2025 Non-covered Recipient Entity
Neurology Center Of New England Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226082629
Principal investigator 1 TG Therapeutics, Inc. $3,202.32 03/10/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200043
Principal investigator 1 TG Therapeutics, Inc. $56,720.00 03/01/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200021
Principal investigator 1 Ipsen Innovation $36.43 02/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, Pc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288542
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,034.20 01/31/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND, PC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190308748
Principal investigator 1 TG Therapeutics, Inc. $13,552.00 01/31/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200023
Principal investigator 1 TG Therapeutics, Inc. $5,563.37 01/31/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND P.C.
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200027
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,072.55 01/27/2025 Non-covered Recipient Entity
Neurology Center Of New England, PC
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235995455
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $85,374.54 01/16/2025 Non-covered Recipient Entity
Neurology Center Of New England, PC
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235995457
Principal investigator 1 Roche Products Limited $338.00 01/09/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627714
Principal investigator 1 Roche Products Limited $338.00 01/09/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627718
Principal investigator 1 Roche Products Limited $338.00 01/09/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627722
Principal investigator 1 Roche Products Limited $338.00 01/09/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627725
Principal investigator 1 Roche Products Limited $338.00 01/09/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NEW ENGLAND PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211627731